A study by Perier-Muzet et al. found that melanoma patients older than 65 years, despite having higher cumulative illness rating scores, had better PFS and OS after receiving ICI, particularly after receiving an anti-PD-1 treatment [35]. Here, PDCD1 is linked to melanoma.